OBJECTIVE： To optimize the formulation of Budesonide sustained-release tablet. METHODS： Using the cumulative releases in 2， 4， 8 h as investigation indexes， central composite design-response surface method was used to optimize the amount of hydroxypropylcellulose L （HPC-L）， amount of soybean phosphatides， and filler （fixed total 200 mg） lactose - microcrystalline cellulose mass ratio in the formulation of Budesonide sustained-release tablet， and the verification test was conducted. The release behaviors of prepared sustained-release tablet and original preparation in pH 7.2， 7.0， 6.8 phosphate buffer were compared. RESULTS： The optimal formulation was as follow as budesonide of 9 mg， HPC-L of 46.49 mg， soybean phosphatides of 9.23 mg， filler lactose-microcrystalline cellulose mass ratio of 1 ∶ 2.9； the cumulative releases in 2， 4， 8 h were 21.9％， 50.1％， 99.5％， the relative errors with predicted values （22.0％， 50.0％， 98.5％） were 0.45％， 0.20％， 1.02％ （n＝3）， respectively. Compared with cumulative release of original preparation， the f2 was higher than 50. CONCLUSIONS： Budesonide sustained-release tablet is successfully prepared， which shows similar release behavior to original preparations.